Evogene revenue contracts to $0.3 million as Q1 net loss widens
Evogene (NASDAQ:EVGN), a computational biology and chemistry company specializing in small molecule design for the pharmaceutical and agricultural industries, disclosed its financial results for the first quarter ended March 31, 2026.
The period was marked by a contraction in consolidated revenues and an increased net loss, heavily impacted by non-cash financial expenses.
Total revenues for the first quarter fell to approximately $0.3 million, down from the $2.3 million generated during the corresponding three-month period in 2025.
The company’s quarterly net loss widened to approximately $5.9 million, compared to a net loss of $3 million reported in the first quarter of the prior year.
The increased net loss was significantly driven by approximately $3.8 million in financing expenses.
These charges were primarily tied to a warrant inducement transaction finalized in February 2026, which successfully generated approximately $3.4 million in gross proceeds to bolster the company's capital reserves.
Evogene concluded the quarter with a liquid balance sheet consisting of roughly $13.1 million in cash, cash equivalents, and short-term bank deposits.
Despite the top-line pressures on the parent entity, Evogene’s specialized operational structure is projected to benefit from cash inflows via its independent subsidiaries.
Non-core business units Lavie Bio and Biomica recently obtained formal court approvals to distribute corporate dividends.
Under these arrangements, Evogene expects to receive an aggregate cash distribution of approximately $4.25 million over the course of the 2026 calendar year, providing non-dilutive funding to support its proprietary ChemPass AI discovery platform.
